Overall , @ patients were randomly assigned to receive axitinib at a starting dose of @-mg twice daily continuously plus pemetrexed @ mg/m ( @ ) and cisplatin @ mg/m ( @ ) on day @ of up to six @-day cycles ( arm I ) ; axitinib on days @ through @ of each cycle plus pemetrexed/cisplatin ( arm II ) ; or pemetrexed/cisplatin alone ( arm III ) .